REFERENCES
- Stevens, J.F., and C.S. Maier: Acrolein: Sources, metabolism, and biomolecular interactions relevant to human health and disease. Mol. Nut. Food Res. 52:7–25 (2008).
- Pugliatti, M., H.F. Harbo, and T. Holmoy, et al.: Environmental risk factors in multiple sclerosis. Acta Neurol. Scand. 117(Suppl 188):34–40 (2008).
- Giovannoni, G., and G. Ebers: Multiple sclerosis: The environment and causation. Curr Opin Neurology 20:261–268 (2007).
- Milo, R., and E. Kahana: Multiple sclerosis: Geoepidemiology, genetics, and the environment. Autoimmun. Rev. 9:A387–A394 (2010).
- Operskalski, E.A., B.R. Visscher, R.M. Malmgren, et al. A case-control study of multiple sclerosis. Neurology. 39:825–829 (1989).
- Chumlea, W.C., C.M. Schubert, A.F. Roche, et al.: Age at menarche and racial comparisons in US girls. Pediatrics. 111(1):110–113 (2003).
- National Institute for Occupational Safety and Health (NIOSH): NIOSH Pocket Guide to Chemical Hazards. Publication No. 2010-168c. Available at http://www.cdc.gov/niosh/npg/ (accessed January 2014).
- Ramagopalan, S.V., R. Dobson, U.C. Meier, et al.: Multiple sclerosis: Risk factors, prodromes, and potential causal pathways. Lancet Neurol. 9(7):727–739 (2010).
- Ascherio, A., and K. Munger: Environmental risk factors for multiple sclerosis. Part 1: The role of infection. Ann. Neurol. 61(4):288–299 (2007).
- Ascherio, A., and K. Munger: Epidemiology of multiple sclerosis: From risk factors to prevention. Semin. Neurol. 28(1):17–28 (2008).
- Ebers, G.C., A.D. Sadovnick., D.A. Dyment, et al.: Parent-of-origin effect in multiple sclerosis: Observations in half-siblings. Lancet 363(9423):1733–1734 (2004).
- Wood, P.L., M.A. Khan, and J.R. Moskal: The concept of “aldehyde load” in neurodegenerative mechanisms: Cytotoxicity of the polyamine degradation products hydrogen peroxide, acrolein, 3-aminopropanal, 3-acetamidopropanal and 4-aminobutanal in a retinal ganglion cell line. Brain Res. E-pub 1145:150–156 (2007).
- Leung, G., W. Sun, L. Zheng, et al.: Anti-acrolein treatment improves behavioral outcome and alleviates myelin damage in experimental autoimmune encephalomyelitis mouse. Neuroscience 173:150–155 (2011).
- Krishnan, C., A.I. Kaplin, R.A. Brodsky, et al.: Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch. Neurol. 65(8):1044–1051 (2008).
- (Centers for Disease Control and Prevention (CDC): “Cancer Clusters.” Available at http://www.cdc.gov/nceh/clusters/about.htm (accessed November 2013).
- Rothman, K.J.: A sobering start for the cluster busters’ conference. Am. J. Epidemiol. 132(Suppl 1):S1–S13. (1990).
- Dean, G., and R. Gray: Do nurses or doctors have an increased risk of developing multiple sclerosis? J. Neurol. Neurosurg. Psychiatry. 53(10):899–902 (1990).
- National Institute for Occupational Safety and Health (NIOSH): “NIOSH List of Antineoplastic an Other Hazardous Drugs in Healthcare Settings 2010.” Available at http://www.cdc.gov/niosh/docs/2010-167/pdfs/2010-167.pdf (accessed June 2014).
- Code of Federal Regulations . Washington, DC: U.S. Government Printing Office, Office of the Federal Register.